MEXICO CITY--(BUSINESS WIRE)--Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA*) ("the Company†or "Orbia†) today released unaudited results for the third quarter of 2025. Orbia delivered revenues of $1.97 billion and EBITDA of $295 million for the quarter. Operating cash flow of $271 million represented a conversion rate of 92% of EBITDA for the third quarter of 2025. While the demand environment remains subdued in Polymer Solutions and Building & Infrastructure, market conditions have generally stab ...

Core Insights - Boston Scientific Corp. shares increased over 4% in intra-day trading following the release of third-quarter earnings and revenue that surpassed analyst expectations, driven by strong performance across all business segments [1] Financial Performance - The company reported adjusted earnings per share (EPS) of $0.75, exceeding the consensus estimate of $0.71 [2] - Revenue grew 20.3% year-over-year to $5.07 billion, surpassing forecasts of $4.97 billion [2] - Organic revenue increased by 15.3%, exceeding the company's previous guidance range of 12% to 14% [2] Segment Performance - The Cardiovascular segment experienced significant growth, with revenue up 22.4% [2] - The MedSurg segment also showed strong performance, climbing 16.4% [2] - U.S. sales increased by 27% compared to the same quarter last year, indicating robust domestic demand [2] Future Outlook - Boston Scientific raised its full-year 2025 outlook, now anticipating adjusted EPS between $3.02 and $3.04, compared to the consensus of $2.98 [3] - For the fourth quarter, management guided for EPS between $0.77 and $0.79, above the Wall Street forecast of $0.76 [3]

Core Points - Aurora Cannabis Inc. has scheduled a conference call to discuss its second quarter 2026 financial results on November 5, 2025, at 8:00 a.m. Eastern Time [1][2] - The company will release its financial results before the market opens on the same day [1] - Miguel Martin, Executive Chairman and CEO, and Simona King, CFO, will host the conference call [2] Company Overview - Aurora Cannabis is a leading global medical cannabis company based in Edmonton, Alberta, serving both medical and consumer markets across Canada, Europe, Australia, and New Zealand [3] - The company's brand portfolio includes various adult-use brands such as Drift, San Rafael '71, Daily Special, Tasty's, Being, and Greybeard, as well as medical cannabis brands like MedReleaf, CanniMed, Aurora, and Whistler Medical Marijuana Co [3] - Aurora holds a controlling interest in Bevo Farms Ltd., a major supplier of propagated agricultural plants in North America [3] - The company emphasizes science and innovation, focusing on high-quality cannabis products to lead in medical, wellness, and adult recreational markets [3][4]

Core Insights - GE Vernova Inc. reported third-quarter revenue of $9.97 billion, exceeding analyst expectations of $9.16 billion, representing a 12% year-over-year increase, but adjusted earnings per share were $1.64, below the expected $1.86 [1][2] Revenue and Earnings - The company reaffirmed its 2025 full-year revenue outlook, expecting to reach the upper end of its $36–$37 billion range, slightly below the $37.15 billion consensus [2] - Orders surged 55% organically to $14.6 billion, driven by strong demand in the Power and Electrification segments [2] Backlog and Orders - The backlog increased by $6.6 billion sequentially, with Gas Power equipment reservations rising from 55 to 62 gigawatts [2] - By segment, Power orders rose 50% organically to $7.8 billion, with revenue up 15% to $4.8 billion [3] - Wind orders increased 4% to $1.8 billion, although revenue fell 8% to $2.6 billion [3] - The Electrification unit saw orders more than double to $5.1 billion, while revenue advanced 35% to $2.6 billion [3]

Core Insights - Hilton Worldwide Holdings Inc. shares increased over 4% following the company's raised full-year earnings guidance and better-than-expected third-quarter results, reflecting optimism for a sustained rebound in U.S. travel demand [1] Financial Performance - The company raised its full-year adjusted EBITDA forecast to between $3.69 billion and $3.72 billion, an increase from the previous estimate of $3.65 billion to $3.71 billion, surpassing analysts' expectations of $3.68 billion [2] - For the third quarter, Hilton reported adjusted earnings per share of $2.11, exceeding forecasts of $2.05, while revenue rose to $2.11 billion from $1.92 billion year-over-year, also above expectations [3] - Revenue per available room (RevPAR) decreased by 1.1% year-over-year to $119.33, slightly missing projections, but management noted strong pricing and occupancy trends heading into the fourth quarter [3] Industry Context - Industry sentiment has improved recently, supported by positive outlooks from airlines like United Airlines and Delta Air Lines, indicating steady travel activity following earlier slowdowns due to uncertainties from tariff policies [2]

PresentationBenjamin Wolthers Welcome to this webinar sharing the 2-year readout from our Evaxion Phase II study in advanced melanoma. We are very, very happy with the virtual turnout for this call here. And together with the Professor Adnan Khattak, I look forward to sharing results and discussing data and implications of these data with all of you right from this important Phase II study in high-risk melanoma. So if we look into the next hour or so, we will be covering an exciting agenda. Initially, I wi ...

Core Insights - Thermo Fisher Scientific Inc. reported third-quarter earnings and revenue that exceeded analyst expectations, driven by margin expansion and product innovation [1][2] Financial Performance - Adjusted earnings per share were $5.79, surpassing the consensus estimate of $5.50 [1] - Revenue increased by 5% year-over-year to $11.12 billion, exceeding expectations of $10.91 billion [1] - Organic revenue growth was recorded at 3% [1] - Adjusted operating margin improved to 23.3%, up from 22.3% in the prior-year quarter [2] - GAAP earnings per share were $4.27, essentially flat compared to $4.25 a year ago [2] Product Innovation - The company launched several new offerings during the quarter, including the FDA-approved Oncomine Dx Express Test for non-small cell lung cancer and the Olink Target 48 Neurodegeneration panel [2] - These innovations are aimed at aiding research on diseases such as Alzheimer's and Parkinson's [2] Strategic Outlook - Management indicated that innovation and portfolio strength are key drivers of sustainable growth across the business [3]

Oct 22, 2025 5:13 PM Eastern Daylight Time Deluxe to Report Third Quarter 2025 Results on November 5, 2025 Share MINNEAPOLIS--(BUSINESS WIRE)--Deluxe (NYSE: DLX), a Trusted Payments and Data company, will report third quarter 2025 financial results on Wednesday, November 5, 2025, following market-close. On the same day, management will hold an open-access conference call at 5:00 p.m. ET (4:00 p.m. CT). All interested persons may listen to the call by dialing 1.800.330.6730 (conference passcode: 968218). The ...

Oct 22, 2025 5:13 PM Eastern Daylight Time Halper Sadeh LLC Encourages Snap Inc. Shareholders to Contact the Firm to Discuss Their Rights Share Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Snap Inc. (NYSE: SNAP) breached their fiduciary duties to shareholders. If you currently own Snap stock and acquired shares on or bef ...

Core Insights - Wabtec Corporation reported strong third-quarter adjusted earnings, exceeding analyst expectations with adjusted earnings per share of $2.32 compared to estimates of $2.28, and revenue of $2.89 billion, slightly above the expected $2.88 billion [1][2] Financial Performance - Adjusted operating margin expanded by 130 basis points to 21.0%, driven by higher volumes and improved cost efficiency [2] - Total backlog reached $25.6 billion, with a 12-month backlog up 8.4% year-over-year [2] - Freight sales increased 8.4% to $2.09 billion, with equipment sales surging 32% due to stronger locomotive deliveries [2] - Transit segment revenue grew 8.2% to $793 million [2] Future Outlook - Wabtec raised its 2025 adjusted earnings guidance to a range of $8.85–$9.05 per share, an increase of $0.10 at the midpoint [3] - The company maintained its revenue outlook of $10.925–$11.225 billion, implying approximately 6.6% growth at the midpoint [3]